WO1982000095A1 - Thrombosis-prophylatic and curing agent - Google Patents

Thrombosis-prophylatic and curing agent Download PDF

Info

Publication number
WO1982000095A1
WO1982000095A1 PCT/JP1981/000148 JP8100148W WO8200095A1 WO 1982000095 A1 WO1982000095 A1 WO 1982000095A1 JP 8100148 W JP8100148 W JP 8100148W WO 8200095 A1 WO8200095 A1 WO 8200095A1
Authority
WO
WIPO (PCT)
Prior art keywords
thrombosis
acid
blood
platelet aggregation
compound
Prior art date
Application number
PCT/JP1981/000148
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Oil & Fats Co Ltd Nippon
Original Assignee
Naito C
Miyazaki Y
Kawai J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naito C, Miyazaki Y, Kawai J filed Critical Naito C
Priority to DE19813152174 priority Critical patent/DE3152174A1/de
Publication of WO1982000095A1 publication Critical patent/WO1982000095A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention relates to a prophylactic and therapeutic agent for thrombosis.
  • Thrombosis is a pathological phenomenon in which blood clots are formed by coagulation of blood platelets due to the aggregation of platelets in the heart or blood vessels of a living body. It causes stenosis and occlusion of blood vessels, and causes ischemic lesions and infarcts in major organs such as the heart, brain, and lungs, causing dysfunction of these organs and causing clinically serious diseases. You The causes of the above-mentioned thrombus formation have not been clearly elucidated so far. Forces, basically changes in the properties of blood vessel walls, changes in blood flow, and changes in blood components are considered as factors.
  • platelet adhesion / aggregation factors such as recent coagulation factors, fibrinolytic factors, and prostaglandin, as well as reticular system functions, etc., are considered to be involved in the above thrombus and intravascular blood coagulation. Attention is being given. However, thrombosis occurs when the above factors are abnormally closely related to each other and are intertwined.
  • Anticoagulants have been introduced. Typical examples are sodium citrate, heparin, coumarin derivatives, Indion derivatives are known, and these anticoagulants are not suitable for thrombus that has already been produced in view of their mechanism of action. dissolve the Les Effect is rather than, Ri total of the improvement of the blood clot ⁇ 0 binary states to follow, not only Ru effective der to prevent stomach Shi prevent recurrence of thrombosis. or recent years thrombus actively Enzyme preparations such as oral kinase and streptokinase have been developed as agents that dissolve and improve blood flow, that is, thrombolytic agents, especially antigen-free. In addition, non-pyrogenic peroxidase has been widely used in clinical practice 5.
  • platelet hyperactivity is closely related to the formation of thrombus. It has been pointed out that, for its prevention or treatment, platelet function inhibitors, so-called antiplatelet agents such as platelet membrane stabilizers, adenylyl cycle activators, Inhibition of sponge esterase, aspirin, and inhibition of LASS (labile aggregatio n st imulat ing-sub s tance) production of phosphorus, non-steroid anti-inflammatory agents, etc.
  • LASS labile aggregatio n st imulat ing-sub s tance
  • the present invention relates to (all-Z) -4,7,10,13,16,19-docosahexaenoic acid and pharmacologically acceptable salts and esters of the acid.
  • Thrombosis prevention and treatment characterized by the fact that it contains at least one species selected from the group consisting of There is one remedy.
  • the prophylactic and therapeutic agent for thrombosis of the present invention is based on the use of the above-mentioned specific polyunsaturated fatty acids and their derivatives as active ingredients, and is used for deep vein thrombosis, limb thrombosis, and embolism.
  • S It has an excellent effect on the prevention and treatment of various thrombosis such as pulmonary embolism, retinal vein thrombosis, coronary artery thrombosis, cerebral thrombosis, etc. obtain.
  • the above-mentioned erectile component compound of the present invention has good absorbability from the intestinal tract, can be used internally, and is safe in blood. Therefore, the effect lasts for a long time, and it can be taken for a long period of time. Is not shown much.
  • Esters and amito's can be used as the active ingredient similarly to the above compounds.
  • the pharmacologically acceptable salts and esters are typically sodium salts, potassium salts, potassium salts, aluminum salts.
  • the prophylactic and therapeutic agent for thrombosis of the present invention can be administered alone as an active ingredient compound, but is usually administered in the form of a pharmaceutical composition together with a pharmaceutical carrier.
  • a pharmaceutical carrier Used as a carrier; fillers, extenders, binders, humectants, humectants, disintegrants, surfactants, lubricants commonly used to prepare medicinal products according to their form And diluents or excipients.
  • various forms can be selected according to the purpose, and typical examples are tablets, pills, powders, solutions, suspensions, emulsions, and granules. Preparations, capsules, suppositories, injections (solutions, suspensions, etc.) and the like.
  • the carrier may be, for example, lactose, sucrose, sodium chloride, sodium pudose solution, urea, starch, calcium carbonate.
  • $ & Says $ & ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Sugar, glucose, glycerin, starch solution, gelatin solution ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Binders such as phenolic cellulose, cellulose, phenolic cellulose, phenolic lime, polyvinyl pyrrolidone, starch, and aldol Sodium sodium formate, powdered zinc, powdered aluminum, powdered sodium carbonate, calcium carbonate, touin, sodium rauryl sulfate Disintegration
  • the carrier may be, for example, excipients such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, kaolin, talc, etc.
  • the carrier may be, for example, polyethylene glycol, viscose, high-grade alcohol, or high-grade alcohol. Esters, gelatin, semi-synthetic glycerides, etc. can be used. Prepared as injection ij
  • solutions and suspensions are preferably sterilized and isotonic with blood, and may be used in the form of solutions, emulsions, and suspensions.
  • diluents such as water, ethyl alcohol, propylene glycol, and ethoxylate fetal isosteryl alcohol , Polio fiso d'isosteal real call, poliox ethylensolbito, solvitan ester, etc. can be used.
  • glycerin may be contained in the preparation in an amount sufficient to prepare an isotonic solution, such as salt and glucose.
  • antioxidants for example, butylated hydroxytoluene, propyl gallate, quinone , And-Tocopherol, etc., as well as conventional solubilizers, buffers, soothing agents, preservatives, coloring agents, flavors, flavors, sweeteners, and other pharmaceuticals Sase! This can be done, and certain antioxidants may promote anti-thrombotic effects.
  • the amount of the active ingredient compound to be contained in the pharmaceutical composition is not particularly limited and may be widely selected, but is usually in the whole composition / weight.
  • the active ingredient compound of 2 to / is almost equivalent to the free acid weight based on the weight of free acid when using the agent as an example. 1 included .
  • the agent for preventing and treating thrombosis of the present invention is not particularly limited in its use, and may be administered in a method according to various forms.
  • tablets, pills, solutions, suspensions, emulsions, granules In the case of injections, it is administered orally, and in the case of injections, it is administered as a simple mixture with normal replenisher such as glucose and amic acid and administered intravenously.
  • Intramuscularly, intradermally, subcutaneously or intraperitoneally, alone as needed, rectally in the case of suppositories, and intracavity in the case of women Can be administered.
  • the dosage of the preparation C is appropriately selected according to the administration method, the patient's symptoms, etc., and generally the active ingredient compound is expressed in terms of free acid in terms of free acid / / to so mg / k ⁇ -day. , Preferably ⁇ 2 ⁇ ⁇ . i73 ⁇ 4 3 ⁇ 4i.day, which is usually divided into j to j times per day o
  • the present invention also provides a prophylactic and therapeutic agent for thrombosis in a food form containing such a specific fat or oil.
  • a prophylactic and therapeutic agent for & thrombosis which is not considered a conventional example, is provided.
  • FIG. 2 shows the inhibitory effect of the compounds of the present invention on platelet aggregation induced by ADP, collagen and arachidonic acid, respectively.
  • the graphs show changes over time in the turbidity (absorbance) of the blood sample used in the experimental examples.
  • (1) indicates the test compound concentration S00lA
  • (2) indicates the test compound concentration. Same concentration 0
  • a collagen to be used as a platelet aggregation inducer As a collagen to be used as a platelet aggregation inducer, a collagen reagent “Horm” manufactured by Hormon Chemie (Nishi-Ata) was used. In the form of saline solution, ADP and arachidonic acid are available from Sigma, respectively.
  • OMPI ⁇ Use as a saline solution and an ethanol solution, respectively.
  • the platelet count in the plasma obtained by the centrifugation at // ⁇ rpm above is determined by the following formula: and, the Re this diluted Let 's platelet count that Do the X / 0 8 or above P PP to prepare a PRP (platelet rich plasma).
  • O PI i ADP solution i prepared with physiological saline or ethanol to a concentration that gives 20 jx9 / m for gen and 50 i9ZmT for arachidonic acid, and collagen Solution 20 Hi and arachidonic acid solution / ⁇ are respectively added to induce platelet aggregation.
  • the platelet aggregation inhibitory effect of the test compound at each concentration is examined by continuously recording the turbidity change (absorbance change) caused by the above-mentioned stagnation. .
  • FIG. 10 is a graph showing a similar platelet aggregation inhibitory effect at a time of / min.
  • the horizontal axis represents time
  • the vertical axis represents absorbance change.
  • the middle curve (1) is the concentration of the test compound at SOO /
  • the line (2) is 2S0fi9 / n
  • the curve is 9 / m
  • the curve is the control solution (with no test compound added, control), the curve (S) EPA for comparison
  • the active compound of the present invention is susceptible to any platelet aggregation induced by ADP, collagen and arachidonic acid.
  • ADP platelet aggregation induced by ADP, collagen and arachidonic acid.
  • the preferred degree of application is slightly different, it is evident that it has a sufficient inhibitory effect.
  • the active ingredient compound of the present invention has an inhibitory effect about ⁇ 2 times that of the active ingredient compound. It is found to be effective as a therapeutic agent.
  • Fig. 7 shows the results of the inhibitory effect on ADP-induced platelet aggregation
  • Fig. 7 shows the results of inhibition of collagen-induced platelet aggregation
  • Fig. 7 shows the results of inhibition on collagen-induced platelet aggregation
  • Fig. 7 shows the inhibition of arachidonic acid-induced platelet aggregation.
  • the result of production II ? Each is shown in the figure. In each figure, curve (1) does not show the test compound, and the curve does not show the control raft (control).
  • test compound 5 mid was used as the test compound, which was dissolved in soo-ethanol.
  • OMPI («2 ri; am, inner diameter / 3 n).
  • the extracorporeal circuit was filled with saline containing heparin (Z00 to ⁇ 00 units) and kept in a thermostat kept at soil / ° C.
  • ADP / from the front of the above filter Administer 5 saline solutions in about 5 transfers to induce platelet aggregation. The force before and after the filter is measured, and the difference is calculated and used as an indicator of the degree of cohesion. After administration of ADP J times every minute, calculate the above difference, determine the degree of coagulation of the control ⁇ -l, and continue the test compound! ?

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP1981/000148 1980-06-27 1981-06-27 Thrombosis-prophylatic and curing agent WO1982000095A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19813152174 DE3152174A1 (de) 1980-06-27 1981-06-27 Thrombosis-prophylatic and curing agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP80/88072800627 1980-06-27
JP8807280A JPS5735512A (en) 1980-06-27 1980-06-27 Preventive and remedy for thrombosis

Publications (1)

Publication Number Publication Date
WO1982000095A1 true WO1982000095A1 (en) 1982-01-21

Family

ID=13932644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1981/000148 WO1982000095A1 (en) 1980-06-27 1981-06-27 Thrombosis-prophylatic and curing agent

Country Status (3)

Country Link
JP (1) JPS5735512A (enrdf_load_stackoverflow)
GB (1) GB2090529B (enrdf_load_stackoverflow)
WO (1) WO1982000095A1 (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3307244A1 (de) * 1982-08-06 1984-02-16 Theodor 6450 Hanau Splithoff Traeger zur aufnahme von vorzugsweise einem schild
DE3615710A1 (de) * 1986-05-09 1987-11-26 Hoechst Ag Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701469A (en) * 1983-04-15 1987-10-20 Roussel Uclaf Triglycerides, process for therapeutical applications and compositions containing them
US4607052A (en) * 1983-04-15 1986-08-19 Roussel-Uclaf Triglycerides, dietetic and therapeutical applications and compositions containing them
JPH0615469B2 (ja) * 1984-05-09 1994-03-02 テルモ株式会社 脂肪輸液剤
JPS60248610A (ja) * 1984-05-23 1985-12-09 Nitsusui Seiyaku Kk 糖尿病合併症の予防および治療剤
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
GB8729751D0 (en) * 1987-12-21 1988-02-03 Norsk Hydro As Feed additive & feed containing such additive
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
FR2643637B1 (fr) * 1989-02-27 1991-09-20 Natura Medica Laboratoires Complexe d'ion calcium avec au moins un acide gras insature, agent biomediateur comprenant un tel complexe, composition pharmaceutique l'incorporant et extraits de plantes ou d'organes d'animaux en contenant
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
JP6399655B2 (ja) 2012-01-06 2018-10-03 オムセラ・ファーマシューティカルズ・インコーポレイテッド 遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
AR095182A1 (es) 2012-05-07 2015-09-30 Omthera Pharmaceuticals Inc Composiciones de estatinas y ácidos grasos omega-3
CN104958725A (zh) * 2015-07-05 2015-10-07 四川金堂海纳生物医药技术研究所 一种治疗静脉血栓形成的内服药物及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54154533A (en) * 1978-05-26 1979-12-05 Wellcome Found Protecting and treating preparation of thrombsis
JPS5515444A (en) * 1978-05-26 1980-02-02 Wellcome Found Prescribed substance for thrombosis prevention and remedy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54154533A (en) * 1978-05-26 1979-12-05 Wellcome Found Protecting and treating preparation of thrombsis
JPS5515444A (en) * 1978-05-26 1980-02-02 Wellcome Found Prescribed substance for thrombosis prevention and remedy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3307244A1 (de) * 1982-08-06 1984-02-16 Theodor 6450 Hanau Splithoff Traeger zur aufnahme von vorzugsweise einem schild
DE3615710A1 (de) * 1986-05-09 1987-11-26 Hoechst Ag Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen

Also Published As

Publication number Publication date
GB2090529B (en) 1985-04-24
GB2090529A (en) 1982-07-14
JPS5735512A (en) 1982-02-26
JPH0141604B2 (enrdf_load_stackoverflow) 1989-09-06

Similar Documents

Publication Publication Date Title
WO1982000095A1 (en) Thrombosis-prophylatic and curing agent
JP2593879B2 (ja) ジピリダモル又はモピダモルと、０―アセチルサリチル酸とを含む製薬組成物、及びその製造方法
JPH0813742B2 (ja) 血液凝固阻止剤
JPH0749374B2 (ja) 抗炎症剤
GB1580444A (en) Pharmaceutical compositions
US6235795B1 (en) Natural mixture composed of higher primary aliphatic alcohols obtained from bee wax for the treatment of gastric and duodenal ulcers that also present antiinflamatory activity
Hansen et al. Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa).
JPS6257605B2 (enrdf_load_stackoverflow)
JPH0114206B2 (enrdf_load_stackoverflow)
US4097602A (en) Method of inhibiting blood platelet aggregation
JPH04501419A (ja) 高血圧症の治療
JPS5973524A (ja) 血栓性疾患処置剤
Hanson et al. Effect of dazoxiben on arterial graft thrombosis in the baboon.
US6465526B1 (en) Natural mixture composed of higher primary aliphatic alcohols obtained from bee wax for the treatment of gastric and duodenal ulcers that also present antiinflamatory activity
EP0113235B1 (en) Antithrombotic and/or antihypertensive compositions
EP0261439B1 (en) Medicament for curing arteriosclerosis, comprising pyrimido (2,1-b) benzothiazole derivative
JPH0586931B2 (enrdf_load_stackoverflow)
JPS5978118A (ja) 血栓症治療および予防剤
JPS6213A (ja) 血栓症予防及び治療用組成物
US4788200A (en) Method and composition for treating arteriosclerosis
JP7609882B2 (ja) イカリチンの医薬使用
JPS6054313A (ja) 腸管吸収性ヘパリン組成物
JP2515114B2 (ja) 血小板凝集抑制剤
JPS6041612A (ja) 血栓症予防及び治療剤
EP0055702A1 (en) Antithrombotic treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DE GB US

RET De translation (de og part 6b)

Ref document number: 3152174

Country of ref document: DE

Date of ref document: 19820812

WWE Wipo information: entry into national phase

Ref document number: 3152174

Country of ref document: DE